Table 3 Combination of the three variables with statistical significant associations at baseline visit or at six month visit.

From: Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab

 

Baseline EDSS*

Baseline EBNA-1 IgG titers**

HHV-6 variation (0–6 months)***

NEDA-3

Clinical responders

Therapeutic failure

(All variables below the first quartile)

 < 2.0 (1.0–1.5)

 < 21.5 AU

 > 20% of decrease

75.0%

100.0%

0.0%

(All variables below the median value)

 < 3.0 (1.0–2.5)

 < 23.2 AU

 > 5% of decrease

65.2%

85.2%

3.7%

(All variables above the median value)

 > 3.0 (3.5–7.5)

 > 23.2 AU

 < 5% of decrease

23.5%

40.9%

31.8%

(All variables above the fourth quartile)

 > 4.0 (4.5–7.5)

 > 25.5 AU

 > 5% of increase

0.0%

0.0%

60.0%

  1. *Baseline EDSS: 1st quartile: 2.0; median value: 3.0; 4th quartile: 4.0.
  2. **Baseline EBNA-1 IgG titers: 1st quartile: 21.5 AU; median value: 23.2 AU; 4th quartile: 25.5 AU.
  3. ***HHV-6 variation between IgG titers of the baseline visit and the six months visit: 1st quartile: 20% of decrease; median value: 5% of decrease; 4th quartile: 5% of increase.
Back to article page